Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Am J Transplant. 2020 Apr 28;20(10):2675–2685. doi: 10.1111/ajt.15881

Figure-4: Delayed treatment with CTLA4-Ig plus Bortezomib controls established humoral responses in sensitized mice.

Figure-4:

(A) Experimental design. C57BL/6 WT recipients were immunized with BALB/c donor splenocytes (DST) on D0 and D28. Mice received no treatment (None), CTLA4-Ig (C4-Ig; POD14+), Bortezomib (Btz; D14, D15) or CTLA4-Ig and Bortezomib (Both). (B) Anti-BALB/c IgG were assessed from D0–42 post-DST (N=4/group). (C) Experimental design. Mice received BALB/c skin transplants on POD-70 and POD0, and treated from POD14, as indicated. (D) Anti-BALB/c IgG from –D70 to D70 (N=4/group). (E) Quantification of PC subsets in bone marrow (N=4–36) and (F) total IgG secreting cells (Left) and anti Kd-IgG secreting cells (Right) (N=4–5) in the bone marrow of naïve or post-2° skin transplantation, on POD28. Experimental groups are: not receiving (None) or receiving CTLA4-Ig and Bortezomib both (Both; from POD14). Y axis represents total cells retrieved per mouse from at least two independent experiments. Data are presented as Mean ± SEM and statistically significant differences assessed by one way ANOVA. (*P <0.05) (**P <0.01) (***P<0.001).